Acrivon Therapeutics, Inc. (ACRV) — 10-Q Filings
All 10-Q filings from Acrivon Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Acrivon Narrows Q3 Loss Amidst Cash Burn, Clinical Progress
— Nov 13, 2025 Risk: high
Acrivon Therapeutics, Inc. (ACRV) reported a net loss of $18.234 million for the three months ended September 30, 2025, an improvement from a net loss of $22.44 -
Acrivon's Losses Widen Amid Increased R&D for Cancer Therapies
— Aug 13, 2025 Risk: high
Acrivon Therapeutics, Inc. (ACRV) reported a net loss of $21.0 million for the three months ended June 30, 2025, an increase from $18.8 million for the same per -
Acrivon Therapeutics Files Q1 2025 10-Q
— May 14, 2025 Risk: medium
Acrivon Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition and results of operations, inclu -
Acrivon Therapeutics Files Q3 2024 10-Q
— Nov 13, 2024 Risk: medium
Acrivon Therapeutics, Inc. filed its Q3 2024 10-Q report on November 13, 2024, for the period ending September 30, 2024. The company's fiscal year ends on Decem -
Acrivon Therapeutics Q2 2024: Cash Down, R&D Up, $100M Raised
— Aug 13, 2024 Risk: medium
Acrivon Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $109.3 million as of June 30, 2
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX